- Home
- CMPX
as 07-26-2024 4:00pm EST
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 131.0M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 424.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $3.01 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Compass Therapeutics Inc. News
CMPX Breaking Stock News: Dive into CMPX Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
GlobeNewswire
2 months ago
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
2 months ago
Compass Therapeutics Announces CEO Transition
GlobeNewswire
2 months ago
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
GlobeNewswire
2 months ago
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GlobeNewswire
2 months ago
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
GlobeNewswire
3 months ago
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compare CMPX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMPX Compass Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.